Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. Lainez N, et al. BMC Cancer. 2016 Feb 22;16:135. doi: 10.1186/s12885-016-2084-9. BMC Cancer. 2016. PMID: 26906039 Free PMC article.
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J, González-Del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez Á, Cuevas Sanz JM, Muñoz Del Toro JR, Useros Rodríguez E, García García-Porrero Á, Vázquez S. Puente J, et al. BMC Cancer. 2019 Aug 5;19(1):766. doi: 10.1186/s12885-019-5974-9. BMC Cancer. 2019. PMID: 31382926 Free PMC article.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B. Marín-Aguilera M, et al. Int J Cancer. 2019 Oct 1;145(7):1970-1981. doi: 10.1002/ijc.32238. Epub 2019 Mar 23. Int J Cancer. 2019. PMID: 30807643
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer.
Jiménez N, Reig Ò, Montalbo R, Milà-Guasch M, Nadal-Dieste L, Castellano G, Lozano JJ, Victoria I, Font A, Rodriguez-Vida A, Carles J, Suárez C, Domènech M, Sala-González N, Fernández PL, Rodríguez-Carunchio L, Díaz S, Prat A, Marín-Aguilera M, Mellado B. Jiménez N, et al. Among authors: sala gonzalez n. Front Oncol. 2020 Nov 2;10:594023. doi: 10.3389/fonc.2020.594023. eCollection 2020. Front Oncol. 2020. PMID: 33224888 Free PMC article.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.
Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma.
Sabaté-Ortega J, Albert-Carrasco M, Escribano-Ferrer C, Grau-Manrubia G, Fina-Planas C, López-Núñez C, Teixidor-Vilà E, Bujons-Buscarons E, Montañés-Ferrer C, Sala-González N. Sabaté-Ortega J, et al. Among authors: sala gonzalez n. Front Oncol. 2024 May 2;14:1354127. doi: 10.3389/fonc.2024.1354127. eCollection 2024. Front Oncol. 2024. PMID: 38807761 Free PMC article.
Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.
Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P; en representación del Grupo Guard de Investigación Multidisciplinar en Tumores genitourinarios. Borque-Fernando Á, et al. Among authors: sala gonzalez n. Actas Urol Esp (Engl Ed). 2024 Nov;48(9):623-631. doi: 10.1016/j.acuroe.2024.05.008. Epub 2024 May 11. Actas Urol Esp (Engl Ed). 2024. PMID: 38740263 Free article. English, Spanish.
15 results